Concord Wealth Partners’s Myriad Genetics MYGN Stock Holding History

Concord Wealth Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-24	Closed	-$348	–	1142
2022 Q4	$348	Buy	+24	New	+$447	﹤0.01%	1178
2022 Q3	–	Sell	-24	Closed	–	–	759
2022 Q2	$0	Sell	24 -73	-75%	-$1.52K	﹤0.01%	1324
2022 Q1	$2K	Buy	97 +73	+304%	+$1.87K	﹤0.01%	1112
2021 Q4	$1K	Buy	+24	New	+$695	﹤0.01%	1243

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Concord Wealth Partners's MYGN Position: Q1 2023 in Review

Concord Wealth Partners sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 24 shares — an estimated $348 sold.

Concord Wealth Partners first reported a position in MYGN in Q4 2021 and held it in 4 quarters. The position peaked at $2K in Q1 2022. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

Concord Wealth Partners reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
Concord Wealth Partners sold 24 Myriad Genetics shares in Q1 2023, an estimated $348.
Concord Wealth Partners first reported a position in Myriad Genetics in Q4 2021 and held it in 4 quarters.
Concord Wealth Partners's Myriad Genetics position peaked at $2K in Q1 2022.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Concord Wealth Partners's 13F filing for Q1 2023, filed 26 Apr 2023.